Johnson & Johnson’s TECVAYLI may redefine second-line myeloma care after MajesTEC-9
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.
Pharma & Biotech